Drugs / CD133+ bone marrow-derived stem cells
CD133+ bone marrow-derived stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02144987 | Apr 2013 → Sep 2014 | Asherman syndrome | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD133+ bone marrow-derived stem cells | “Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study.” PMID 27005892 ↗ Mar 2016 |
| Known as | BMDSCs | “Could cell therapy using autologous peripheral blood CD133+ bone marrow-derived stem cells (BMDSCs) offer a safe and efficient therapeutic approach for patients with refractory...” PMID 27005892 ↗ Mar 2016 |
| Known as | CD133+ BMDSCs | “SUMMARY ANSWER: In the first 3 months, autologous cell therapy, using CD133+ BMDSCs in conjunction with hormonal replacement therapy, increased the volume and duration of...” PMID 27005892 ↗ Mar 2016 |
| Modality | Cell therapy | “Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study.” PMID 27005892 ↗ Mar 2016 |
| Route | Other | “immediately delivered into the spiral arterioles by catheterization” PMID 27005892 ↗ Mar 2016 |